Cannabinoids, cannabis, and cannabis-based medicine for pain management: A protocol for an overview of systematic reviews and a systematic review of randomised controlled trials

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Emma Fisher, Bath University, Oxford University, Oxford, UK.
  • ,
  • Christopher Eccleston, Bath University, Oxford University, Oxford, UK., Universiteit Gent
  • ,
  • Louisa Degenhardt, UNSW, National Drug & Alcohol Research Centre
  • ,
  • David P. Finn, National University of Ireland Galway
  • ,
  • Nanna B. Finnerup
  • Ian Gilron, Aarhus University Hospital, Queen's University, Kingston, Ontario
  • ,
  • Simon Haroutounian, Division of Clinical and Translational Research, Internal Medicine, Washington University in St. Louis, School of Medicine
  • ,
  • Elliot Krane, Department of Structural Biology, Stanford University School of Medicine
  • ,
  • Andrew S.C. Rice, Imperial College London, London, UK.
  • ,
  • Michael Rowbotham, University of California, San Francisco, California Pacific Medical Center Research Institute
  • ,
  • Mark Wallace, University of California, San Diego
  • ,
  • R. Andrew Moore, Oxford University, Oxford, UK.

Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life. Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these reviews we will determine the harm and benefit of CBM from the current literature and will interpret the findings in light of the quality of evidence and reviews included. We will search online databases and registries in any language for systematic reviews and randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcome measures will also be included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).

Original languageEnglish
Article numbere741
JournalPain Reports
Volume4
Issue3
Number of pages8
DOIs
Publication statusPublished - 2019

    Research areas

  • Cannabinoids, Cannabis, Meta-analysis, Overview, Pain, Protocol, Systematic review

See relations at Aarhus University Citationformats

ID: 164039040